Of note, the findings that HCT 116, p53 WT, and KRAS-Mut-(G13D) showed the greatest sensitivity to the treatments could be explained by the observation in the clinics where patients with KRAS-G13D appeared to respond positively to drugs like cetuximab (used in treatment for metastatic colorectal cancer), suggesting this mutation is an exception to the rule that KRAS mutations are undruggable and confer resistance to drugs such as epidermal growth factor receptor (EGFR) inhibitors [72]. This evidence concerns the gene TP53 and metastatic colorectal cancer.